loading...| Preferred Name |
dienogest |
|
| Synonyms |
STS 557 |
|
| Definitions |
An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with potential antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87238" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87238" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000743773 |
|
| altLabel |
STS 557 17-hydroxy-3-oxo-19-nor-17.alpha.-pregna-4,9-diene-21-nitrile ZK 37659 M 18575 19-norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17.alpha.)- |
|
| CAS Registry |
65928-58-7 |
|
| cui |
C0057916 C2987675 C4722383 C0143781 |
|
| DATE FIRST PUBLISHED |
2012-12-07 |
|
| Date last modified |
2012-12-14 |
|
| definition |
An orally-active, semisynthetic, fourth generation, nonethinylated progestogen with potential antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive. Upon oral administration, dienogest binds intracellular progesterone receptors which then translocate to the nucleus where the drug-receptor complex interacts with progesterone response elements, thus altering the expression of target genes. Dienogest reduces the production of estradiol, prevents ovulation and alters the cervical mucus and endometrium. In addition, dienogest appears to suppress the expression of cell cycle regulator cyclin D1. Altogether, this may prevent the growth of endometrial epithelial cells and may reduce symptoms associated with leiomyoma. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87238" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87238" NCI Thesaurus) |
|
| NCI ID |
C87238 |
|
| notation |
CDR0000743773 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
dienogest |
|
| tui |
T125 T109 T121 |